Strahlentherapie und Onkologie最新文献

{"title":"Oncological outcomes of breast cancer patients after planned IORT boost with low-kV x-rays-results of the TARGIT BQR prospective phase IV trial.","authors":"Lukas Goerdt, Janina Pömsl, Uta Kraus-Tiefenbacher, Viktoria Brück, Christina Kaiser, Ralf Keymer, Yasser Abo-Madyan, Katharina Fleckenstein, Sebastian Berlit, Benjamin Tuschy, Marc Sütterlin, Frederik Wenz, Elena Sperk","doi":"10.1007/s00066-025-02412-0","DOIUrl":"10.1007/s00066-025-02412-0","url":null,"abstract":"<p><strong>Purpose: </strong>The TARGIT BQR (boost quality registry) phase IV trial investigates clinical outcomes of breast cancer patients with standard external-beam radiotherapy (EBRT) of the whole breast and intraoperative radiotherapy (IORT) with low-kV x‑rays as an anticipated tumor bed boost in a real-world setting.</p><p><strong>Methods: </strong>Intraoperative radiotherapy was performed immediately after breast-conserving surgery in one fraction. External-beam radiotherapy and systemic treatment were given according to the German S3 guideline for breast cancer and local tumor board recommendations. Outcome parameters were death, local recurrence, metastasis, local lymph node recurrence, and ipsilateral and contralateral invasive breast cancer. Kaplan-Meier estimates were used to calculate overall survival, metastasis-free survival, local recurrence-free survival, and disease-free survival.</p><p><strong>Results: </strong>From 10 centers, 1133 patients were recruited. This analysis included 871 patients with 879 cancers, with a median follow-up of 36 months (up to 12 years). An IORT boost was performed in 82% and whole-breast irradiation in 84%. Overall survival was 98.4% after 3 years, 96.8% after 5 years, and 95.4% after 10 years (16 deaths; 1.8%). Metastasis and local recurrence occurred in 11 patients each (1.3%). At 5 years, the local control rate was 97.4% and local recurrence-free survival was 94.4%. Ipsilateral breast cancer occurred in 2 patients, contralateral breast cancer in 3 patients, and local lymph node recurrence in 2 patients. Disease-free survival was 92.9% after 5 years and 82.6% after 10 years.</p><p><strong>Conclusion: </strong>This phase IV trial confirms previously reported outcomes on upfront IORT boost, with excellent disease-control outcomes.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":"169-177"},"PeriodicalIF":2.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12872669/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144094851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chemo-/radiotherapy-induced cardiomyopathy: roles of mitochondria and endoplasmic reticulum.","authors":"Muath Suliman, Farag M A Altalbawy, Malathi H, Syeda Wajida Kazmi, Ashish Sharma, M Ravi Kumar, Hassan Thoulfikar A Alamir, Faraj Mohammed, Abed J Kadhim, Merwa Alhadrawi","doi":"10.1007/s00066-025-02471-3","DOIUrl":"10.1007/s00066-025-02471-3","url":null,"abstract":"<p><p>Chemo-/radiotherapy-induced cardiomyopathy is a clinical challenge for patients with cancer, characterized by detrimental effects on cardiac structure and function. To date, numerous experimental and clinical investigations have revealed that numerous mechanisms, such as oxidative damage, contribute to chemo-/radiotherapy-induced cardiomyopathy. Chronic oxidative stress and reactive oxygen species (ROS) production following damage to mitochondria and the endoplasmic reticulum (ER) play a fundamental role in the progression of cell death, inflammation, and fibrosis, leading to heart failure and unusual changes in the heart structure. This review delves into the mechanisms of cardiotoxicity induced by chemotherapy and radiotherapy, highlighting the pivotal role of mitochondrial dysfunction and subsequent oxidative stress and cell death. The interplay between mitochondrial and ER dysfunction can also be offered as a paramount factor in the development of cardiomyopathy. We review how damage to these organelles may trigger cardiac injury through crosstalk with other mechanisms such as activation of pro-oxidant enzymes, inflammation, fibrosis, and other important processes.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":"209-232"},"PeriodicalIF":2.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145252806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long term outcomes of prostate cancer patients aged 55 years or younger treated with definitive radiotherapy: Trod 09-005 study.","authors":"Caglayan Selenge Beduk Esen, Aysenur Elmali, Birhan Demirhan, Ozan Cem Guler, Selvi Tabak Dincer, Ilknur Alsan Cetin, Meral Kurt, Mustafa Akin, Ertugrul Senturk, Serap Akyurek, Halil Cumhur Yildirim, Gulhan Guler Avci, Pelin Altinok, Hamit Basaran, Gokhan Ozyigit, Pervin Hurmuz, Cem Onal","doi":"10.1007/s00066-025-02470-4","DOIUrl":"10.1007/s00066-025-02470-4","url":null,"abstract":"<p><strong>Purpose: </strong>Evidence on the use of definitive radiotherapy (RT) in younger prostate cancer (PCa) patients is limited, with no national-level studies systematically evaluating oncologic outcomes and treatment-related toxicity in this population. This study aimed to assess oncologic outcomes and toxicity of definitive prostate RT in patients aged 55 years or younger.</p><p><strong>Methods: </strong>Records of 180 PCa patients aged ≤ 55 years treated with definitive RT ± androgen deprivation therapy across 12 cancer centers were retrospectively reviewed. Primary endpoints included freedom from biochemical failure (FFBF) and PCa-specific survival (PCSS). Secondary endpoints were overall survival (OS), acute/late genitourinary (GU) and gastrointestinal (GI) toxicities, local recurrence (LR), and distant metastasis (DM).</p><p><strong>Results: </strong>Median age was 54 years; median PSA at diagnosis was 10.4 ng/mL. Risk group distribution was 29% low-, 29% intermediate-, and 42% high-risk. Median RT dose was 76 Gy delivered in 38 fractions. After a median follow-up of 106.2 months, local recurrence (9%), distant metastasis (7%), and isolated PSA progression (3%) were noted. The 8‑year FFBF, PCSS, and OS were 85.7%, 93.8%, and 90.3%, respectively. Univariate analysis identified PSA, clinical T stage, Gleason score (GS), and risk group as significant prognostic factors for FFBF and PCSS. Multivariate analysis showed advanced stage and high GS independently predicted worse FFBF and PCSS. Acute and late grade ≥ 2 GU toxicity occurred in 12% and 6%, and GI toxicity in 11% and 3%.</p><p><strong>Conclusion: </strong>Definitive radiotherapy is a safe and effective treatment for prostate cancer patients aged ≤ 55 years. Prospective studies are needed to confirm these findings.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":"139-148"},"PeriodicalIF":2.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145125995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tenth anniversary of the Young DEGRO Team Trial-reflecting on the past, shaping the future.","authors":"Felix Ehret, Michael Oertel, Alexander Rühle","doi":"10.1007/s00066-025-02417-9","DOIUrl":"10.1007/s00066-025-02417-9","url":null,"abstract":"","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":"123-128"},"PeriodicalIF":2.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12872678/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival determinants and toxicity of second-course radiotherapy for isolated nodal recurrences in breast cancer.","authors":"Cezara Cheptea, Youlia Kirova, Jeremy Baude, Fatima Laki, Alain Fourquet, Pierre Loap","doi":"10.1007/s00066-025-02409-9","DOIUrl":"10.1007/s00066-025-02409-9","url":null,"abstract":"<p><strong>Background: </strong>Isolated nodal recurrence (INR) after localized breast cancer is rare, with an incidence of less than 1%. Curative management typically includes surgical resection, often with axillary lymph node dissection (ALND), followed by regional nodal radiotherapy. However, evidence-based guidelines remain limited due to the rarity of this clinical scenario. The aim of this study was to evaluate survival determinants and the acute and long-term toxicities associated with second-course regional nodal irradiation as part of curative strategies for INR after localized breast cancer.</p><p><strong>Materials and methods: </strong>This retrospective study included 11 patients with localized breast cancer who developed ipsilateral, nonmetastatic INR between 2003 and 2019. All patients were treated with curative intent, including regional nodal irradiation. Overall survival (OS), cancer-specific survival (CSS), metastasis-free survival (MFS), local control, and treatment toxicities were analyzed. Survival probabilities were calculated using the Kaplan-Meier method, and Cox regression was used to assess prognostic factors.</p><p><strong>Results: </strong>The 5‑year OS and CSS were 71.6%, while MFS was 62.3%. Inclusion of internal mammary chain (IMC) irradiation significantly improved OS, CSS, and MFS (p < 0.01). Triple-negative breast cancer (TNBC) INRs were associated with worse survival outcomes. Acute grade 2 toxicities included radiodermatitis (36.4%), and late grade 2 toxicities were limited to fibrosis (18.2%). No cardiac, pulmonary, or grade 3 or higher toxicities were reported.</p><p><strong>Conclusion: </strong>This study highlights the favorable survival outcomes and safety profile of contemporary curative strategies for INRs following localized breast cancer, with a 5-year OS rate exceeding historical benchmarks. Internal mammary chain irradiation appears to improve survival without increased toxicity. However, the poor prognosis associated with TNBC INR underscores the need for effective systemic therapies. Prospective multicenter trials are essential to validate these findings and optimize treatment protocols.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":"160-168"},"PeriodicalIF":2.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144032432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stereotactic heart ablative radiotherapy (SHARP): a prospective multicentric phase II trial.","authors":"Aurélie Gaasch, Sebastian N Marschner, Philipp Hoegen-Saßmannshausen, Elisabetta Sandrini, Juliane Hörner-Rieber, Nicolaus Andratschke, Panagiotis Balermpas, Luca Boldrini, Angela Romano, Michael Reiner, Maximilian Niyazi, Lars Lindner, Ludwig Weckbach, Nicola Fink, Christian Hagl, Claus Belka, Stefanie Corradini","doi":"10.1007/s00066-026-02504-5","DOIUrl":"https://doi.org/10.1007/s00066-026-02504-5","url":null,"abstract":"<p><strong>Background: </strong>Cardiac tumors are exceedingly rare with metastatic involvement representing the most frequent form of malignancy within the heart. In patients presenting with inoperable primary or recurrent malignant cardiac sarcomas or cardiac/epicardial/pericardial metastases, stereotactic body radiotherapy (SBRT) serves as an alternative local treatment to surgery or may, in some cases, constitute the sole viable local treatment modality. To date, there are only case reports or small retrospective studies assessing SBRT dose and toxicity for cardiac SBRT. The goal of this prospective multicentric observational study is to systematically evaluate the feasibility, toxicity and outcome of magnetic resonance-guided stereotactic body radiation therapy (MRgSBRT) in the management of primary and secondary cardiac malignancies.</p><p><strong>Methods: </strong>The treatment is performed using MR-guided SBRT in five fractions on non-consecutive days (6-8 Gy per fraction prescribed to the 80% isodose). Four study centers participate in this prospective phase II trial (Heidelberg, Munich, Rome, Zurich). Eligible patients who consent to participate in the study will undergo treatment as indicated and approved by an interdisciplinary tumor board. Primary objective is to assess the feasibility and safety of online adaptive MRgSBRT; secondary endpoints are local control and survival outcome, acute and late toxicity, patient-reported outcome as well as technical feasibility of treatment.</p><p><strong>Discussion: </strong>The findings from this study may serve as a foundation for the future integration of cardiac SBRT into clinical practice guidelines for the management of cardiac malignancies.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146087112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Proton beam therapy versus trans-arterial chemoembolization for BCLC stage B hepatocellular carcinoma-a propensity-matched analysis.","authors":"Tzu-Ting Liu, Bing-Shen Huang, Yu-Ming Wang, Chieh-Min Liu, Eng-Yen Huang, Hsin-You Ou, Tsung-Hui Hu, Sheng-Nan Lu, Chao-Hung Hung, Yen-Hao Chen, Chung-Shih Chen, Jen-Yu Cheng","doi":"10.1007/s00066-026-02505-4","DOIUrl":"10.1007/s00066-026-02505-4","url":null,"abstract":"","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146012276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Shaping the future of radiation oncology education: results of a nationwide student survey from Germany.","authors":"Hendrik Dapper, Michael Oertel, Hilke Vorwerk, Sophia Drabke, Diana Steinmann, Emmanouil Fokas, Heinz Schmidberger, Nanna E Wielenberg, Matthias Mäurer, Philipp Linde","doi":"10.1007/s00066-025-02493-x","DOIUrl":"https://doi.org/10.1007/s00066-025-02493-x","url":null,"abstract":"<p><strong>Background and purpose: </strong>Radiation oncology (RO) is a key component of cancer care and should be adequately represented in undergraduate medical education. In light of medical training reforms in German medical education and rising expectations for competency-based, practice-oriented learning, this nationwide survey explored medical students' perspectives on RO teaching and its future development.</p><p><strong>Materials and methods: </strong>A cross-sectional online survey was conducted from 2023 to 2025 across all 38 German medical faculties. Developed by the Working Group on Teaching of the German Society for Radiation Oncology (DEGRO), the 49-item questionnaire addressed curriculum structure, teaching quality, preferred formats, and interest in RO.</p><p><strong>Results: </strong>Among 1112 participants, 739 completed the survey. Although 96% viewed RO as being essential to cancer care, 62% felt it was underrepresented in the curriculum. Students called for more interdisciplinary and patient-centered teaching and showed high interest in digital and hybrid learning formats. Notably, 60.5% favored interdisciplinary oncology formats including RO, and nearly half expressed interest in elective RO courses.</p><p><strong>Conclusion: </strong>Despite its recognized importance, RO remains inconsistently represented in medical education. Embedding RO in interdisciplinary oncology modules and expanding digital, longitudinal, and flexible teaching formats could enhance its visibility and relevance. Given students' strong interest in more in-depth exposure, optional and elective formats should be further developed to meet modern educational expectations.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145912858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Bacterial decolonization with mupirocin ointment reduces severe radiation-induced oral mucositis in nasopharyngeal carcinoma: results of a randomized phase 3 trial].","authors":"Cas Stefaan Dejonckheere, Lukas Käsmann","doi":"10.1007/s00066-025-02472-2","DOIUrl":"10.1007/s00066-025-02472-2","url":null,"abstract":"","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":"109-111"},"PeriodicalIF":2.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145233374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Radiation protection procedures in the context of the new Medical Research Act: what has changed, what has not? A joint overview by the German Society for Radiation Oncology (DEGRO) and the Federal Office for Radiation Protection (BfS)].","authors":"Elena Sperk, Matthias Habeck, Felix Giani, Dirk Vordermark, Mechthild Krause, Stefan Rieken, Ursula Nestle, Bastian Breustedt","doi":"10.1007/s00066-025-02488-8","DOIUrl":"10.1007/s00066-025-02488-8","url":null,"abstract":"","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":"5-12"},"PeriodicalIF":2.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12819552/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145565150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}